1. Judith A. Miller, Kerri Thai, James W. Scholey.

Angiotensin II type 1 gene polymorphism predicts

response to losartan and angiotensin II. Kidney International, vol 56, pp 2173-2180, 1999;
2. https://pubchem.ncbi.nlm.nih.gov/compound/3961 , accesat la 10.03.2020- ora 09:33;
3. https://promediq.ro/infarct/, accesat la 10.03.2020-ora 10:22;
4. Suhrs HE, Ibsen H. Angio-oedema and medication that interferes with the renin-
angiotensin-aldosterone system--a systematic review. Ugeskr Laeger. 2012 Mar
12;174(11):724-729;
5. JS. Alpert, K. Thygesen, E. Antman, JP. Bassand. Myocardial infarction redefined- A consensus
document of the joint European society of cardiology. Sep;36(3):959-69, 2000;
6. Steckelings UM, Unger Th. The renin-angiotensin-aldosterone system. In: Manual of
Hypertension of the European Society of Hypertension. Informa Healthcare. 2008.
7. Dzau V. The cardiovasculary continuum and renin-angiotensin-aldosterone blockade. J
Hypertens. 2005;23(suppl): S9-S17.
8. Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease. Jam Coll Cardiol
2006; 48: 1–11;
9.
10. Yan A, Yan R, Liu P. Pharmacotherapy for chronic heart failure: evidence from recent
clinical trials. Ann Intern Med 2005; 142: 132-145;
11. Bilić M, Munjas-Samarin R, Ljubanović D, Horvatić I, Galesić K. Effects of ramipril and
valsartan on proteinuria and renal function in patients with nondiabetic proteinuria. Coll
Antropol. 2011; 35(4): 1061-1066;
12. Richard E. Klabunde PhD: Cardiovascular Physiology Concepts 2nd edition, published
by Lippincott Williams&Wilkins, 2011;
13. Cervenka L, Vanecková I, Husková Z. Pivotal role of angiotensin II receptor subtype 1A
in the development of two-kidney, one-clip hypertension: study in angiotensin II receptor
subtype 1A knockout mice ; J Hypertens. 2008; 26(7): 1379-1389;
14. Nawarskas J, Townsend R, Cirigliano M, Spinler S. Effect of aspirin on blood pressure in
hypertensive patients taking enalapril or losartan. Am J Hypertens. 1999;12 8 Pt 1:784-9;
15. Kambayashi Y, NaKao K, Mukoyama M, et al. (1990) : Isolation and sequence
determination of human brain natriuretic peptide in human atrium. FEBS Lett 259 :341-
345 ;
16. I.Haulica. Fiziologie umana, Editura medicala, 2009;
17. Müller-Fielitz H, Landolt J, Heidbreder M.et al. Improved insulin sensitivity after long-
term treatment with AT1 blockers is not associated with PPARγ target gene regulation.
Endocrinology. 2012; 153(3): 1103-1115;
18.  Sun SX, Lee KY, Bertram CT, Goldstein JL. Withdrawal of cox-2 inhibitors rofecoxib and valdecoxib: impact
on NSAID and PPI prescriptions and expenditures. Curr Med Opin 2007; 8: 1859-1866;
19. Matchar DB., McCrory DC., Orlando LA. et al. Systematic review: comparative effectiveness of
angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers for treating essential
hypertension. Ann Intern Med 2008; 148: 16-29.
20. https://olnafu.ru/s%C4%83n%C4%83tate/83629-lorista-pastile-instruc%C8%9Biuni-de-utilizare-
recenzii.html , accesat la 12.03.2020-ora 11:15;
21. https://www.spitalul-municipal-timisoara.ro/data_files/content/sectii/clinica-de-cardiologie-
ascar/protocol-diagnostic-tratament-hipertensiune-arteriala.pdf, accesat la 12.03.2020-ora
14:05;
22. https://www.youtube.com/watch?v=YUPVfQjuXAM , accesat la 14.03.2020-ora 8:50;
23. https://www.anm.ro/_/_PRO/pro_3018_06.12.10.pdf , accesat la 14.03.2020-ora 11:03;
24. https://www.synevo.ro/shop/angiotensina-ii/, accesat la 14.03.2020-ora 15:01;
25. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in
high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial.
Optimal trial in myocardial infarction with angiotensin II antagonist Losartan. Lancet
2002; 360: 752-760;
26. Matchar DB., McCrory DC., Orlando LA. et al. Systematic review: comparative
effectiveness of angiotensinconverting enzyme inhibitors and angiotensin II receptor
blockers for treating essential hypertension. Ann Intern Med 2008; 148: 16-29;
27. Julius S., Kjeldsen SE., Weber M. et al; VALUE Trial group. Outcomes in hypertensive
patients at high cardiovascular risk treated with regimens based on valsartan or
amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031;
28. Conlin PR, Moore TJ, Swartz SL, Barr E, Gazdick L, Fletcher C, et al. Effect of
indomethacin on blood pressure lowering by captopril and losartan in hypertensive
patients. Hypertension, 2000; 36:461-5
29. Paul R. Conlin, Thomas J. Moore, Stephen L. Swartz, Eliav Barr, Lisa Gazdick, Charlena
Fletcher, Paul DeLucca and Laura Demopoulos, “Effect of Indomethacin on Blood
Pressure Lowering by Captopril and Losartan in Hypertensive Patients”, American Heart
Association, 2000;36:461-465;
30. Olsen ME, Thomsen T, Hassager C, Ibsen H, Dige-Petersen H. Hemodynamic and renal
effects of indomethacin in losartan-treated hypertensive individuals. Am J Hypertens.
1999;12:209–216;
31. Rosaleen J., Anderson David L., Paul W. Groundwater. Organic Spectroscopic Analysis. The Royal
Society of Chemistry, 2004;
32. http://6e.plantphys.net/topic07.01.html , accesat la 26.03.2020-ora 12:45;
33. V. Dumitrescu, N. Dumitrescu, I. Varduca, Analiză instrumentală. Aspecte teoretice şi
practice ale spectrometriei de absorbţie atomică, Ed. Universităţii Bucureşti, 2003;
34. Chimie Analitica si Instrumentala, Horea Iustin NASCU Lorentz JANTSCHI, Academic Pres &
Academic Direct 2006;
35. D. Barca-Galateanu, M. Giurgea, I. Iova, V. Sabini, A. Trutia, R. Titeica, 1966ș
36. https://www.flickr.com/photos/121935927@N06/13580411493, accesat la 2.04.2020- ora 15:06;
37. M. Avram, Gh.D. Mateescu, “Spectroscopia in infrarosu. Aplicatii in chimia organica”,
Bucuresti, Editura Tehnica, 1966;
38. F. Perrin, J. de Phys. 7, 390, 1926; M. A. Eliasevici, “Spectroscopia atomică și
moleculară”, p. 31, 1966;
39. Hery Mitsutake, Ronei J. Poppi, Marcia C. Breitkreitz. Raman Imaging spectroscopy: History,
Fundamentals and Current Scenario of the Technique. Journal of the Brazilian Chemical Society,
vol.30, nr.11, 2019;
40. M. A. Eliasevici, “Spectroscopia atomică și moleculară”, 100, 1966;
41.